ID   TERT_RAT                Reviewed;        1125 AA.
AC   Q673L6; Q1LZ57; Q4U0V7; Q673L3; Q673L5; Q80SU5;
DT   11-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   11-OCT-2004, sequence version 1.
DT   02-OCT-2024, entry version 138.
DE   RecName: Full=Telomerase reverse transcriptase;
DE            EC=2.7.7.49;
DE   AltName: Full=Telomerase catalytic subunit;
GN   Name=Tert {ECO:0000312|RGD:70494};
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1] {ECO:0000305, ECO:0000312|EMBL:AAT09124.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), TISSUE SPECIFICITY, AND
RP   DEVELOPMENTAL STAGE.
RC   STRAIN=Brown Norway {ECO:0000312|EMBL:AAT09124.1};
RX   PubMed=16454671; DOI=10.2174/092986606774502108;
RA   Kaneko R., Esumi S., Yagi T., Hirabayashi T.;
RT   "Predominant expression of rTERTb, an inactive TERT variant, in the adult
RT   rat brain.";
RL   Protein Pept. Lett. 13:59-65(2006).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RC   STRAIN=Brown Norway {ECO:0000269|PubMed:15057822};
RX   PubMed=15057822; DOI=10.1038/nature02426;
RA   Gibbs R.A., Weinstock G.M., Metzker M.L., Muzny D.M., Sodergren E.J.,
RA   Scherer S., Scott G., Steffen D., Worley K.C., Burch P.E., Okwuonu G.,
RA   Hines S., Lewis L., Deramo C., Delgado O., Dugan-Rocha S., Miner G.,
RA   Morgan M., Hawes A., Gill R., Holt R.A., Adams M.D., Amanatides P.G.,
RA   Baden-Tillson H., Barnstead M., Chin S., Evans C.A., Ferriera S.,
RA   Fosler C., Glodek A., Gu Z., Jennings D., Kraft C.L., Nguyen T.,
RA   Pfannkoch C.M., Sitter C., Sutton G.G., Venter J.C., Woodage T., Smith D.,
RA   Lee H.-M., Gustafson E., Cahill P., Kana A., Doucette-Stamm L.,
RA   Weinstock K., Fechtel K., Weiss R.B., Dunn D.M., Green E.D.,
RA   Blakesley R.W., Bouffard G.G., De Jong P.J., Osoegawa K., Zhu B., Marra M.,
RA   Schein J., Bosdet I., Fjell C., Jones S., Krzywinski M., Mathewson C.,
RA   Siddiqui A., Wye N., McPherson J., Zhao S., Fraser C.M., Shetty J.,
RA   Shatsman S., Geer K., Chen Y., Abramzon S., Nierman W.C., Havlak P.H.,
RA   Chen R., Durbin K.J., Egan A., Ren Y., Song X.-Z., Li B., Liu Y., Qin X.,
RA   Cawley S., Cooney A.J., D'Souza L.M., Martin K., Wu J.Q.,
RA   Gonzalez-Garay M.L., Jackson A.R., Kalafus K.J., McLeod M.P.,
RA   Milosavljevic A., Virk D., Volkov A., Wheeler D.A., Zhang Z., Bailey J.A.,
RA   Eichler E.E., Tuzun E., Birney E., Mongin E., Ureta-Vidal A., Woodwark C.,
RA   Zdobnov E., Bork P., Suyama M., Torrents D., Alexandersson M., Trask B.J.,
RA   Young J.M., Huang H., Wang H., Xing H., Daniels S., Gietzen D., Schmidt J.,
RA   Stevens K., Vitt U., Wingrove J., Camara F., Mar Alba M., Abril J.F.,
RA   Guigo R., Smit A., Dubchak I., Rubin E.M., Couronne O., Poliakov A.,
RA   Huebner N., Ganten D., Goesele C., Hummel O., Kreitler T., Lee Y.-A.,
RA   Monti J., Schulz H., Zimdahl H., Himmelbauer H., Lehrach H., Jacob H.J.,
RA   Bromberg S., Gullings-Handley J., Jensen-Seaman M.I., Kwitek A.E.,
RA   Lazar J., Pasko D., Tonellato P.J., Twigger S., Ponting C.P., Duarte J.M.,
RA   Rice S., Goodstadt L., Beatson S.A., Emes R.D., Winter E.E., Webber C.,
RA   Brandt P., Nyakatura G., Adetobi M., Chiaromonte F., Elnitski L.,
RA   Eswara P., Hardison R.C., Hou M., Kolbe D., Makova K., Miller W.,
RA   Nekrutenko A., Riemer C., Schwartz S., Taylor J., Yang S., Zhang Y.,
RA   Lindpaintner K., Andrews T.D., Caccamo M., Clamp M., Clarke L., Curwen V.,
RA   Durbin R.M., Eyras E., Searle S.M., Cooper G.M., Batzoglou S., Brudno M.,
RA   Sidow A., Stone E.A., Payseur B.A., Bourque G., Lopez-Otin C., Puente X.S.,
RA   Chakrabarti K., Chatterji S., Dewey C., Pachter L., Bray N., Yap V.B.,
RA   Caspi A., Tesler G., Pevzner P.A., Haussler D., Roskin K.M., Baertsch R.,
RA   Clawson H., Furey T.S., Hinrichs A.S., Karolchik D., Kent W.J.,
RA   Rosenbloom K.R., Trumbower H., Weirauch M., Cooper D.N., Stenson P.D.,
RA   Ma B., Brent M., Arumugam M., Shteynberg D., Copley R.R., Taylor M.S.,
RA   Riethman H., Mudunuri U., Peterson J., Guyer M., Felsenfeld A., Old S.,
RA   Mockrin S., Collins F.S.;
RT   "Genome sequence of the Brown Norway rat yields insights into mammalian
RT   evolution.";
RL   Nature 428:493-521(2004).
RN   [3] {ECO:0000305, ECO:0000312|EMBL:AAY40300.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-58, AND INDUCTION.
RX   PubMed=16205635; DOI=10.1038/sj.onc.1209140;
RA   Hu B., Tack D.C., Liu T., Wu Z., Ullenbruch M.R., Phan S.H.;
RT   "Role of Smad3 in the regulation of rat telomerase reverse transcriptase by
RT   TGFbeta.";
RL   Oncogene 25:1030-1041(2006).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:CAD29524.1}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA] OF 46-161, AND TISSUE SPECIFICITY.
RC   STRAIN=Fischer {ECO:0000312|EMBL:CAD29524.1};
RX   PubMed=12729609; DOI=10.1016/s0003-2697(03)00091-5;
RA   Holzmann K., Berger W., Mejri D., Cerni C., Sasgary S.;
RT   "Detection and quantification of transcripts for the catalytic subunit TERT
RT   and the RNA component of telomerase in rat tissue.";
RL   Anal. Biochem. 317:120-123(2003).
RN   [5] {ECO:0000305, ECO:0000312|EMBL:DAA01427.1}
RP   IDENTIFICATION.
RC   STRAIN=Brown Norway;
RA   Kim M.H., Choi C.;
RT   "The identification and characterization of rat telomerase catalytic
RT   subunit rTERT mRNA from rat genomic sequence.";
RL   Chonnam Med. J. 41:1-13(2005).
CC   -!- FUNCTION: Telomerase is a ribonucleoprotein enzyme essential for the
CC       replication of chromosome termini in most eukaryotes. Active in
CC       progenitor and cancer cells. Inactive, or very low activity, in normal
CC       somatic cells. Catalytic component of the teleromerase holoenzyme
CC       complex whose main activity is the elongation of telomeres by acting as
CC       a reverse transcriptase that adds simple sequence repeats to chromosome
CC       ends by copying a template sequence within the RNA component of the
CC       enzyme. Catalyzes the RNA-dependent extension of 3'-chromosomal termini
CC       with the 6-nucleotide telomeric repeat unit, 5'-TTAGGG-3'. The
CC       catalytic cycle involves primer binding, primer extension and release
CC       of product once the template boundary has been reached or nascent
CC       product translocation followed by further extension. More active on
CC       substrates containing 2 or 3 telomeric repeats. Telomerase activity is
CC       regulated by a number of factors including telomerase complex-
CC       associated proteins, chaperones and polypeptide modifiers. Modulates
CC       Wnt signaling. Plays important roles in aging and antiapoptosis (By
CC       similarity). {ECO:0000250}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2'-deoxyribonucleoside 5'-triphosphate + DNA(n) =
CC         diphosphate + DNA(n+1); Xref=Rhea:RHEA:22508, Rhea:RHEA-COMP:17339,
CC         Rhea:RHEA-COMP:17340, ChEBI:CHEBI:33019, ChEBI:CHEBI:61560,
CC         ChEBI:CHEBI:173112; EC=2.7.7.49; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00405};
CC   -!- SUBUNIT: Catalytic component of the telomerase holoenzyme complex
CC       composed of one molecule of TERT, one molecule of WRAP53/TCAB1, two
CC       molecules of H/ACA ribonucleoprotein complex subunits DKC1, NOP10, NHP2
CC       and GAR1, and a telomerase RNA template component (TERC). The
CC       telomerase holoenzyme complex is associated with TEP1, SMG6/EST1A and
CC       POT1. The molecular chaperone HSP90/P23 complex is required for correct
CC       assembly and stabilization of the active telomerase. Interacts directly
CC       with HSP90A and PTGES3. Interacts with HSPA1A; the interaction occurs
CC       in the absence of TERC and dissociates once the complex has formed.
CC       Interacts with RAN; the interaction promotes nuclear export of TERT.
CC       Interacts with XPO1. Interacts with PTPN11; the interaction retains
CC       TERT in the nucleus. Interacts with NCL (via RRM1 and C-terminal
CC       RRM4/Arg/Gly-rich domains); the interaction is important for nucleolar
CC       localization of TERT (By similarity). Interacts with SMARCA4 (via the
CC       bromodomain); the interaction regulates Wnt-mediated signaling (By
CC       similarity). Interacts with MCRS1 (isoform MCRS2); the interaction
CC       inhibits in vitro telomerase activity (By similarity). Interacts with
CC       PIF1; the interaction has no effect on the elongation activity of TERT
CC       (By similarity). Interacts with PML; the interaction recruits TERT to
CC       PML bodies and inhibits telomerase activity (By similarity). Interacts
CC       with GNL3L (By similarity). Interacts with isoform 1 and isoform 2 of
CC       NVL (By similarity). Interacts with DHX36 (By similarity). Interacts
CC       with ATF7 (By similarity). {ECO:0000250|UniProtKB:O14746,
CC       ECO:0000250|UniProtKB:O70372}.
CC   -!- SUBCELLULAR LOCATION: Nucleus, nucleolus
CC       {ECO:0000250|UniProtKB:O14746}. Nucleus, nucleoplasm {ECO:0000250}.
CC       Nucleus {ECO:0000305}. Chromosome, telomere. Cytoplasm {ECO:0000250}.
CC       Nucleus, PML body {ECO:0000250}. Note=Shuttling between nuclear and
CC       cytoplasm depends on cell cycle, phosphorylation states, transformation
CC       and DNA damage. Diffuse localization in the nucleoplasm. Enriched in
CC       nucleoli of certain cell types. Translocated to the cytoplasm via
CC       nuclear pores in a CRM1/RAN-dependent manner involving oxidative
CC       stress-mediated phosphorylation at Tyr-697. Dephosphorylation at this
CC       site by SHP2 retains TERT in the nucleus. Translocated to the nucleus
CC       by phosphorylation by AKT (By similarity). {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1 {ECO:0000269|PubMed:16454671};
CC         IsoId=Q673L6-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:16454671}; Synonyms=a
CC       {ECO:0000269|PubMed:16454671};
CC         IsoId=Q673L6-2; Sequence=VSP_052083;
CC       Name=3 {ECO:0000269|PubMed:16454671}; Synonyms=b
CC       {ECO:0000269|PubMed:16454671}, c {ECO:0000269|PubMed:16454671};
CC         IsoId=Q673L6-3; Sequence=VSP_052081, VSP_052082;
CC   -!- TISSUE SPECIFICITY: Isoform 1 and isoform 2 expressed in thymus, liver,
CC       spleen, lung, kidney and testis. High level of inactive isoform 3 in
CC       adult hippocampus, low level in heart, cortex and cerebellum.
CC       {ECO:0000269|PubMed:12729609, ECO:0000269|PubMed:16454671}.
CC   -!- DEVELOPMENTAL STAGE: High activity in cortex at embryonic stage 16 and
CC       postnatal day 2. Low activity in cortex from postnatal day 5.
CC       {ECO:0000269|PubMed:16454671}.
CC   -!- INDUCTION: Down-regulated by TGFbeta in fibroblasts. This inhibition is
CC       mediated by SMAD3. {ECO:0000269|PubMed:16205635}.
CC   -!- DOMAIN: The primer grip sequence in the RT domain is required for
CC       telomerase activity and for stable association with short telomeric
CC       primers. {ECO:0000250}.
CC   -!- DOMAIN: The RNA-interacting domain 1 (RD1)/N-terminal extension (NTE)
CC       is required for interaction with the pseudoknot-template domain of each
CC       of TERC dimers. It contains anchor sites that bind primer nucleotides
CC       upstream of the RNA-DNA hybrid and is thus an essential determinant of
CC       repeat addition processivity (By similarity). {ECO:0000250}.
CC   -!- DOMAIN: The RNA-interacting domain 2 (RD2) is essential for both
CC       interaction with the CR4-CR5 domain of TERC and for DNA synthesis.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Tyr-697 under oxidative stress leads to
CC       translocation of TERT to the cytoplasm and reduces its antiapoptotic
CC       activity. Dephosphorylated by SHP2/PTPN11 leading to nuclear retention.
CC       Phosphorylation at the G2/M phase at Ser-447 by DYRK2 promotes
CC       ubiquitination by the EDVP complex and degradation (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by the EDVP complex, a E3 ligase complex following
CC       phosphorylation at Ser-447 by DYRK2. Ubiquitinated leads to proteasomal
CC       degradation (By similarity). {ECO:0000250}.
CC   -!- MISCELLANEOUS: [Isoform 3]: Inactive form. {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the reverse transcriptase family. Telomerase
CC       subfamily. {ECO:0000255}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY539717; AAT09124.1; -; mRNA.
DR   EMBL; AY539718; AAT09125.1; -; mRNA.
DR   EMBL; AY539719; AAT09126.1; -; mRNA.
DR   EMBL; AY539720; AAT09127.1; -; mRNA.
DR   EMBL; AC123569; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; DQ021473; AAY40300.1; -; Genomic_DNA.
DR   EMBL; AJ440965; CAD29524.1; -; mRNA.
DR   EMBL; AJ440966; CAD29525.2; -; Genomic_DNA.
DR   EMBL; BK000660; DAA01427.1; -; mRNA.
DR   RefSeq; NP_445875.1; NM_053423.1. [Q673L6-1]
DR   AlphaFoldDB; Q673L6; -.
DR   SMR; Q673L6; -.
DR   STRING; 10116.ENSRNOP00000022683; -.
DR   BindingDB; Q673L6; -.
DR   ChEMBL; CHEMBL3108654; -.
DR   PhosphoSitePlus; Q673L6; -.
DR   PaxDb; 10116-ENSRNOP00000022683; -.
DR   Ensembl; ENSRNOT00000022683.5; ENSRNOP00000022683.4; ENSRNOG00000025327.8. [Q673L6-3]
DR   Ensembl; ENSRNOT00000100559.1; ENSRNOP00000076971.1; ENSRNOG00000025327.8. [Q673L6-1]
DR   Ensembl; ENSRNOT00055004705; ENSRNOP00055003476; ENSRNOG00055003019. [Q673L6-1]
DR   Ensembl; ENSRNOT00060044588; ENSRNOP00060036941; ENSRNOG00060025755. [Q673L6-1]
DR   Ensembl; ENSRNOT00065031232; ENSRNOP00065024879; ENSRNOG00065018587. [Q673L6-1]
DR   GeneID; 301965; -.
DR   KEGG; rno:301965; -.
DR   UCSC; RGD:70494; rat. [Q673L6-1]
DR   AGR; RGD:70494; -.
DR   CTD; 7015; -.
DR   RGD; 70494; Tert.
DR   eggNOG; KOG1005; Eukaryota.
DR   GeneTree; ENSGT00390000018531; -.
DR   HOGENOM; CLU_001996_2_0_1; -.
DR   InParanoid; Q673L6; -.
DR   OMA; LAAMKFH; -.
DR   OrthoDB; 55913at2759; -.
DR   PhylomeDB; Q673L6; -.
DR   TreeFam; TF329048; -.
DR   Reactome; R-RNO-171319; Telomere Extension By Telomerase.
DR   Reactome; R-RNO-201722; Formation of the beta-catenin:TCF transactivating complex.
DR   PRO; PR:Q673L6; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000025327; Expressed in liver and 15 other cell types or tissues.
DR   GO; GO:0000781; C:chromosome, telomeric region; ISO:RGD.
DR   GO; GO:0005737; C:cytoplasm; ISO:RGD.
DR   GO; GO:0005829; C:cytosol; IEA:Ensembl.
DR   GO; GO:0042645; C:mitochondrial nucleoid; ISO:RGD.
DR   GO; GO:0005739; C:mitochondrion; IDA:BHF-UCL.
DR   GO; GO:0016607; C:nuclear speck; IEA:Ensembl.
DR   GO; GO:0005730; C:nucleolus; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:RGD.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0005886; C:plasma membrane; ISO:RGD.
DR   GO; GO:0016605; C:PML body; ISO:RGD.
DR   GO; GO:0031379; C:RNA-directed RNA polymerase complex; ISO:RGD.
DR   GO; GO:0000333; C:telomerase catalytic core complex; ISO:RGD.
DR   GO; GO:0005697; C:telomerase holoenzyme complex; ISS:UniProtKB.
DR   GO; GO:1990572; C:TERT-RMRP complex; ISO:RGD.
DR   GO; GO:0003677; F:DNA binding; ISO:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0042803; F:protein homodimerization activity; ISO:RGD.
DR   GO; GO:0051087; F:protein-folding chaperone binding; ISO:RGD.
DR   GO; GO:0003723; F:RNA binding; ISO:RGD.
DR   GO; GO:0003968; F:RNA-dependent RNA polymerase activity; ISO:RGD.
DR   GO; GO:0003964; F:RNA-directed DNA polymerase activity; ISO:RGD.
DR   GO; GO:0003720; F:telomerase activity; ISS:UniProtKB.
DR   GO; GO:0070034; F:telomerase RNA binding; ISO:RGD.
DR   GO; GO:0003721; F:telomerase RNA reverse transcriptase activity; ISO:RGD.
DR   GO; GO:0042162; F:telomeric DNA binding; IBA:GO_Central.
DR   GO; GO:0098680; F:template-free RNA nucleotidyltransferase; ISO:RGD.
DR   GO; GO:0001223; F:transcription coactivator binding; ISO:RGD.
DR   GO; GO:0000049; F:tRNA binding; ISO:RGD.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEP:RGD.
DR   GO; GO:0071897; P:DNA biosynthetic process; ISO:RGD.
DR   GO; GO:0022616; P:DNA strand elongation; ISO:RGD.
DR   GO; GO:0070200; P:establishment of protein localization to telomere; ISO:RGD.
DR   GO; GO:0007005; P:mitochondrion organization; ISO:RGD.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IMP:RGD.
DR   GO; GO:2000773; P:negative regulation of cellular senescence; ISO:RGD.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; IDA:RGD.
DR   GO; GO:2001240; P:negative regulation of extrinsic apoptotic signaling pathway in absence of ligand; ISO:RGD.
DR   GO; GO:0010629; P:negative regulation of gene expression; ISO:RGD.
DR   GO; GO:0043524; P:negative regulation of neuron apoptotic process; IMP:RGD.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; IDA:RGD.
DR   GO; GO:1900087; P:positive regulation of G1/S transition of mitotic cell cycle; IMP:RGD.
DR   GO; GO:0046326; P:positive regulation of glucose import; ISO:RGD.
DR   GO; GO:0042635; P:positive regulation of hair cycle; ISO:RGD.
DR   GO; GO:1902895; P:positive regulation of miRNA transcription; ISO:RGD.
DR   GO; GO:1904751; P:positive regulation of protein localization to nucleolus; ISO:RGD.
DR   GO; GO:2000648; P:positive regulation of stem cell proliferation; ISO:RGD.
DR   GO; GO:1903620; P:positive regulation of transdifferentiation; IMP:RGD.
DR   GO; GO:1904754; P:positive regulation of vascular associated smooth muscle cell migration; IMP:RGD.
DR   GO; GO:1904707; P:positive regulation of vascular associated smooth muscle cell proliferation; IMP:RGD.
DR   GO; GO:0030177; P:positive regulation of Wnt signaling pathway; ISO:RGD.
DR   GO; GO:0031647; P:regulation of protein stability; ISO:RGD.
DR   GO; GO:0090399; P:replicative senescence; ISO:RGD.
DR   GO; GO:0046686; P:response to cadmium ion; IEP:RGD.
DR   GO; GO:0006278; P:RNA-templated DNA biosynthetic process; ISO:RGD.
DR   GO; GO:0001172; P:RNA-templated transcription; ISO:RGD.
DR   GO; GO:0030422; P:siRNA processing; ISO:RGD.
DR   GO; GO:0140745; P:siRNA transcription; ISO:RGD.
DR   GO; GO:0007004; P:telomere maintenance via telomerase; ISS:UniProtKB.
DR   CDD; cd01648; TERT; 1.
DR   Gene3D; 1.10.132.70; -; 1.
DR   Gene3D; 1.10.357.90; -; 1.
DR   Gene3D; 3.30.70.2630; -; 1.
DR   InterPro; IPR043502; DNA/RNA_pol_sf.
DR   InterPro; IPR000477; RT_dom.
DR   InterPro; IPR021891; Telomerase_RBD.
DR   InterPro; IPR003545; Telomerase_RT.
DR   InterPro; IPR049139; TERT_C.
DR   PANTHER; PTHR12066; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   PANTHER; PTHR12066:SF0; TELOMERASE REVERSE TRANSCRIPTASE; 1.
DR   Pfam; PF00078; RVT_1; 1.
DR   Pfam; PF12009; Telomerase_RBD; 1.
DR   Pfam; PF21399; TERT_C; 1.
DR   PRINTS; PR01365; TELOMERASERT.
DR   SMART; SM00975; Telomerase_RBD; 1.
DR   SUPFAM; SSF56672; DNA/RNA polymerases; 1.
DR   PROSITE; PS50878; RT_POL; 1.
PE   2: Evidence at transcript level;
KW   Alternative splicing; Chromosome; Cytoplasm; DNA-binding; Magnesium;
KW   Metal-binding; Nucleotidyltransferase; Nucleus; Phosphoprotein;
KW   Reference proteome; Ribonucleoprotein; RNA-directed DNA polymerase;
KW   Telomere; Transferase; Ubl conjugation.
FT   CHAIN           1..1125
FT                   /note="Telomerase reverse transcriptase"
FT                   /id="PRO_0000245165"
FT   DOMAIN          595..928
FT                   /note="Reverse transcriptase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   REGION          1..239
FT                   /note="RNA-interacting domain 1"
FT                   /evidence="ECO:0000250"
FT   REGION          58..205
FT                   /note="GQ motif"
FT                   /evidence="ECO:0000250"
FT   REGION          137..141
FT                   /note="Required for regulating specificity for telomeric
FT                   DNA and for processivity for primer elongation"
FT                   /evidence="ECO:0000250"
FT   REGION          206..304
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          240..328
FT                   /note="Linker"
FT                   /evidence="ECO:0000250"
FT   REGION          306..528
FT                   /note="Required for oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          329..540
FT                   /note="RNA-interacting domain 2"
FT                   /evidence="ECO:0000250"
FT   REGION          381..511
FT                   /note="QFP motif"
FT                   /evidence="ECO:0000250"
FT   REGION          402..422
FT                   /note="CP motif"
FT                   /evidence="ECO:0000250"
FT   REGION          907..921
FT                   /note="Required for oligomerization"
FT                   /evidence="ECO:0000250"
FT   REGION          923..927
FT                   /note="Primer grip sequence"
FT                   /evidence="ECO:0000250"
FT   REGION          929..1125
FT                   /note="CTE"
FT                   /evidence="ECO:0000250"
FT   MOTIF           332..337
FT                   /note="TFLY; involved in RNA binding"
FT                   /evidence="ECO:0000250|UniProtKB:Q4KTA7"
FT   COMPBIAS        230..244
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         702
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         861
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   BINDING         862
FT                   /ligand="Mg(2+)"
FT                   /ligand_id="ChEBI:CHEBI:18420"
FT                   /ligand_note="catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00405"
FT   SITE            169
FT                   /note="Required for optimal binding of telomeric ssDNA and
FT                   incorporation of nucleotides at the second position of the
FT                   template"
FT                   /evidence="ECO:0000250"
FT   SITE            860
FT                   /note="Required for nucleotide incorporation and primer
FT                   extension rate"
FT                   /evidence="ECO:0000250"
FT   MOD_RES         447
FT                   /note="Phosphoserine; by DYRK2"
FT                   /evidence="ECO:0000250|UniProtKB:O14746"
FT   MOD_RES         697
FT                   /note="Phosphotyrosine; by SRC-type Tyr-kinases"
FT                   /evidence="ECO:0000250|UniProtKB:O14746"
FT   VAR_SEQ         515..615
FT                   /note="EKDTVPAAEHRLRERILAMFLFWLMDTYVVQLLRSFFYITETTFQKNRLFFY
FT                   RKSVWSKLQSIGIRQQLERVQLRELSQEEVKHHQDTWLAMPICRLRFIP -> ACTSFW
FT                   DSPSPSQVSFIFITAGKPSFPWIRRPLRYLETHRVELTHPAWQEGHCPCRRAPSEGEDP
FT                   CHVPVLANGHICGTAAEVILLHHRDHVPEEPPFLLP (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16454671"
FT                   /id="VSP_052081"
FT   VAR_SEQ         616..1125
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16454671"
FT                   /id="VSP_052082"
FT   VAR_SEQ         641..646
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:16454671"
FT                   /id="VSP_052083"
FT   CONFLICT        521
FT                   /note="A -> V (in Ref. 2; DAA01427)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        528
FT                   /note="E -> V (in Ref. 2; DAA01427)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        550..551
FT                   /note="FF -> LL (in Ref. 2; DAA01427)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        583
FT                   /note="L -> P (in Ref. 2; DAA01427)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        630
FT                   /note="M -> L (in Ref. 2; DAA01427)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   1125 AA;  126934 MW;  B8B2A11C914372DF CRC64;
     MPRAPRCPAV RSLLRSRYRE VWPLATFVRR LGLEGSRLVQ PGDPKVFRTL VAQCLVCVPW
     GSQPPPADLS FHQVSSLKEL VSRVVQKLCE RGERNVLAFG FALLNGARGG PPMAFTTSVH
     SYLPNSVTES LCVSGAWMLL LSRVGDDLLV YLLSHCALYL LVPPSCAYQV CGSPLYQICA
     TTDTWSSVPA GYRPTRPVGG NFTNLGSAHQ IKNSGHQEAP KPQALPSRGT KRLLSLTSTN
     VPSAKKARFE PALRVDKGPH RQVVPTPSGK TWAPSPAASP KVPPAAKNLS LKGKASDPSL
     SGSVCCKHKP SSSSLLSSPP QDAEKLRPFT ETRHFLYSRG GGQEELNPSF LLNSLPPSLT
     GARRLVEIIF LGSRPRTSGP FCRTRRLPRR YWQMRPLFQQ LLMNHAKCQY VRFLRSHCRF
     RTANQRVPDA MDTSPSHLTS LLRLHSSPWQ VYGFLRACLR ELVPAGLWGT RHNERRFLKN
     VKKFISLGKY AKLSLQELMW RVKVEDCHWL RSSPEKDTVP AAEHRLRERI LAMFLFWLMD
     TYVVQLLRSF FYITETTFQK NRLFFYRKSV WSKLQSIGIR QQLERVQLRE LSQEEVKHHQ
     DTWLAMPICR LRFIPKLNGL RPIVNMSYGM DTRAFGKKKQ TQCFTQSLKT LFSVLNYERT
     KHPNLMGASV LGTSDSYRIW RTFVLRVRAL DQTPRMYFVK ADVTGAYDAI PQDKLVEIVA
     NIIRRSESMY CIRQYAVVQK DSQGQVHKSF RRQVSTLSDL QPYMGQFTKH LQDSDASALR
     NSVVIEQSIS MNETGSSLLH FFLRFVRHSV VKIDGRFYVQ CQGIPQGSSL STLLCSLCFG
     DMENKLFAEV QQDGLLLRFV DDFLLVTPHL AHAKAFLSTL VHGVPEYGCM INLQKTVVNF
     PVETGALGGA APHQLPAHCL FPWCGLLLDT RTLEVFCDYS GYGRTSIKMS LTFQGVSRAG
     KTMRYKLLSV LRLKCHGLFL DLQVNSLQTV CINIYKIFLL QAYRFHACVI RLPFGQHVRK
     NHAFFLGIIS NLASCCYAIL KVKNPGVSLR AKGAPGSFPP EATRWLCYQA FLLKLAAHSV
     TYKCLLGPLR TAQKQLCRKL PEATMTLLKT AADPALSTDF QTILD
//
